

Kwok Chiu Chang, Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4159010/publications.pdf>

Version: 2024-02-01

27
papers

1,631
citations

567144

15
h-index

526166

27
g-index

28
all docs

28
docs citations

28
times ranked

2300
citing authors

#	ARTICLE	IF	CITATIONS
1	ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 777-778.	2.5	3
2	How does metformin act as a host-directed agent in tuberculosis associated with diabetes mellitus?. Journal of Thoracic Disease, 2020, 12, 1124-1126.	0.6	5
3	Does oxidative stress contribute to antituberculosis drug resistance?. Journal of Thoracic Disease, 2019, 11, E100-E102.	0.6	3
4	Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing. Journal of Clinical Microbiology, 2019, 57, .	1.8	19
5	Can vitamin C help in managing tuberculosis associated with diabetes mellitus?. Respiriology, 2019, 24, 819-820.	1.3	2
6	Management of adverse reactions to high-dose moxifloxacin used in multidrug-resistant tuberculosis treatment programmes. Respiriology, 2019, 24, 201-203.	1.3	1
7	Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong. European Respiratory Journal, 2018, 51, 1800159.	3.1	11
8	Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	5
9	Recent controversies about <sc>MDR</sc> and <sc>XDR</sc>: <sc>G</sc>lobal implementation of the <sc>WHO</sc> shorter <sc>MDR</sc> regimen and bedaquiline for all with <sc>MDR</sc>?. Respiriology, 2018, 23, 36-45.	1.3	52
10	Vitamin C and Mycobacterium tuberculosis Persists. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	6
11	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	6.3	452
12	Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	45
13	New drugs and regimens for tuberculosis. Respiriology, 2018, 23, 978-990.	1.3	22
14	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine, the, 2017, 5, 291-360.	5.2	459
15	Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Update 2012. Respiriology, 2013, 18, 8-21.	1.3	54
16	Can Intermittent Dosing Optimize Prolonged Linezolid Treatment of Difficult Multidrug-Resistant Tuberculosis?. Antimicrobial Agents and Chemotherapy, 2013, 57, 3445-3449.	1.4	47
17	WHO Group 5 Drugs and Difficult Multidrug-Resistant Tuberculosis: a Systematic Review with Cohort Analysis and Meta-Analysis. Antimicrobial Agents and Chemotherapy, 2013, 57, 4097-4104.	1.4	80
18	Pyrazinamide May Improve Fluoroquinolone-Based Treatment of Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 5465-5475.	1.4	48

#	ARTICLE	IF	CITATIONS
19	â€Z ^S -MDR-TBâ€™™ versus â€Z ^R -MDR-TBâ€™™: improving treatment of MDR-TB by identifying pyrazinamide susceptibility. <i>Emerging Microbes and Infections</i> , 2012, 1, 1-4.	3.0	42
20	Linezolid for multidrug-resistant tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 502-503.	4.6	8
21	Treatment of tuberculosis and optimal dosing schedules. <i>Thorax</i> , 2011, 66, 997-1007.	2.7	47
22	Pyrazinamide Susceptibility Testing in Mycobacterium tuberculosis: a Systematic Review with Meta-Analyses. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4499-4505.	1.4	117
23	The Best Approach to Reintroducing Tuberculosis Treatment after Hepatotoxicity Is Still Open to Debate. <i>Clinical Infectious Diseases</i> , 2010, 51, 366-367.	2.9	9
24	Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1551-1561.	1.3	34
25	Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. <i>Thorax</i> , 2010, 65, 271-276.	2.7	50
26	A systematic review of rapid drug susceptibility tests for multidrug-resistant tuberculosis using rifampin resistance as a surrogate. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 99-122.	1.6	7
27	How flu-like syndromes contribute to termination of weekly rifapentine-based TB preventive therapy is still poorly predictable. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	0